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used as both a proﬁle and single score measure. LiSat-11 is a
generic validated checklist for self-perceived satisfaction with
life. A Finnish, age-matched male population cohort was used
for comparison. RESULTS: A total of 194 patients provided data
for analysis at baseline and outcome at 3 months. The changes
observed (baseline to endpoint) were as follows: average usage
of ED tablets per four weeks increased from 4.7 to 9.7, inter-
course attempts from 6.4 to 10.6, and the success rate of inter-
courses from 79% to 92%. At baseline, the 15D score was higher
for the study patients than for the comparator population (0.924
vs. 0.902). Nevertheless, signiﬁcant improvement (baseline to
endpoint) was reported on the 15D dimensions of mobility,
depression, distress (all p < 0.01), and sexual activity (p < 0.001);
and life in general (p < 0.05), leisure (p < 0.01), sexual life, family
life, and partnership relation (all p < 0.001) domains of LiSat-
11. CONCLUSIONS: When patients switched from other oral
ED medication to tadalaﬁl, improvement was seen in 3 of 15
dimensions of 15D and in 5 out of 11 domains of LiSat-11,
including the closeness items: sexual life, partnership relation,
and family life.
PIH19
ESTIMATING UTILITY IN ROTAVIRUS GASTROENTERITIS IN
CHILDREN UNDER FIVE IN THE UK
Martin A1, Cotrell S2
1GlaxoSmithKline UK Limited, Uxbridge, UK, 2IMS Health, London,
England
OBJECTIVE: To estimate the health state utility of differing
severities of gastro-enteritis associated with rotavirus infection in
children under ﬁve. METHODS: Health state descriptions were
developed based on the major symptoms of gastro-enteritis infec-
tion. Health states for children who could be treated at home and
those requiring hospitalisation were presented to GPs (N = 25),
and for hospitalised cases, health states for children with two
levels of dehydration were presented to paediatricians (N = 25).
Both GPs and paediatricians were asked to score these health
states using the EQ-5D questionnaire for children in two age
bands (< 18 months, 1.5–5 years). Scores were modiﬁed to take
into account the limited capacity for mobility and self-care among
children in this age range. Utility estimates were calculated from
these scores using standard methodology. RESULTS: From GP
scores subjects requiring or not hospitalisation have a mean utility
value (95% CI) of 0.425 (95 CI: 0.330; 0.520) and 0.781 (95 CI:
0.678; 0.884) in children <18 months, and 0.200 (95 CI: 0.049;
0.352) and 0.688 (95 CI: 0.553; 0.824) in children 1.5 yrs–5 yrs
respectively. From paediatrician scores, mean utility values for
hospitalised cases with 3–8% and ≥9% dehydration were 0.595
(95 CI: 0.528; 0.662) and 0.256 (95 CI: 0.157; 0.354) in chil-
dren <18 months, and 0.634 (95 CI: 0.549; 0.718) and 0.077 (95
CI: −0.057; 0.210) in children 1.5 yrs–5 yrs respectively. In each
case, conﬁdence intervals between severe and less severe health
states did not overlap. CONCLUSION: Gastroenteritis associ-
ated with rotavirus has a signiﬁcant impact on the health related
quality of life in children under ﬁve. This study provides useful
estimates of health state utilities for economic evaluation of inter-
ventions to prevent rotavirus infection.
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OBJECTIVE: Demonstrate using conjoint analysis to obtain gen-
eralized, nonlinear, time-tradeoff estimates of quality-adjusted
life-years (QALYs) for clinically relevant durations and severities
of acute, non-fatal conditions such as vasomotor symptoms.
METHODS: A self-administered, web-enabled, graded-pairs
conjoint-analysis survey elicited women’s preferences for the
treatment of vasomotor symptoms. The included treatment
attributes are frequency and severity of vasomotor symptoms
(daytime hot ﬂashes and nighttime sweats) and duration of these
symptoms. Participants also considered vasomotor-symptom,
treatment-related side effects. Observed tradeoffs between
symptom duration and symptom relief were used to calculate
generalized conjoint time equivalents for speciﬁed health states
without ﬁrst calculating utilities anchored at 0 and 1. RESULTS:
A total of 523 women with a mean age of 52 years completed
the survey. For these women, improvement from severe (severe
>6 hot ﬂushes a day and >3 sweats a night) to moderate (mod-
erate 3–6 hot ﬂushes a day and 1–3 sweats a night) vasomotor
symptoms over a 7-year treatment period is equivalent to 3.7
years of normal health, while improvement from moderate to
mild (mild 1–2 hot ﬂushes a day and no night sweats) symptoms
is equivalent to 4.4 years of normal health. QALY beneﬁts of
symptom relief are larger for younger women (<= 2) than for
older women (>52). For example, an improvement from moder-
ate to mild is equivalent to 3.3 years of normal health for
younger women, where it is to 6.8 years of normal health for
older women. CONCLUSIONS: Conjoint analysis is a feasible
method for estimating QALYs directly for acute health states.
This approach avoids ad hoc approaches such as the chaining
method. Its advantages over standard-gamble and time-tradeoff
methods include avoiding clinically irrelevant tradeoffs involv-
ing death or life expectancy, avoiding restrictive assumptions
such as linear time preferences, and eliciting preferences in the
realistic context of both efﬁcacy and side-effect risks.
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Erectile dysfunction (ED) is deﬁned as the persistent or recurring
incapacity to achieve or maintain sufﬁcient rigidity of the penis
to be able to have satisfactory sexual intercourse. OBJECTIVE:
To determine the clinical response to treatment (patient satis-
faction, onset of action and reproducibility of the effect) in
patients with ED, with or without other concomitant diseases.
METHODS: A retrospective, epidemiological study was con-
ducted in which we collected demographic data, medical and
sexual history, concomitant medication, diagnostic and thera-
peutic procedures applied to ED and the clinical response to the
prescribed treatment in male patients over 18 years of age who
had visited their doctor in the 3 months prior to the start of the
study. RESULTS: data was collected from 5281 patients. The
most prevalent associated disorders were cardiovascular
(28.6%), endocrine (23.7%) and genitourinary (15.4%). A total
of 77.1% of the patients with concomitant disorders indicated
they were satisﬁed with the erection obtained (sufﬁcient for inter-
course) (90.9% of the patients without other associated disor-
ders; p < 0.0001). A totalof he patients with concomitant
diseases referred they were satisﬁed with the onset of action of
the treatment (91.1% without other associated disorders; p <
0.0001). 75.8% of the patients with concomitant diseases were
conﬁdent to obtain and maintain a sufﬁcient erection at each new
attempt (90.0% without other associated disorders; p < 0.0001).
Clinical response was better in patients with cardiovascular or
endocrine conditions vs. genitourinary disorders (p < 0.03; p <
0.04). The mean prescribed dose was 15.9 mg (SD 5.2) of var-
denaﬁl, 18.6 mg (SD 6.9) of tadalaﬁl and 60.6 mg (SD 23.7) of
